EFFECT-HF demonstrates a significantly beneficial effect of Ferinject® on exercise capacity among patients with CHF and iron deficiency - confirms findings of previous studies
December 07, 2016 01:00 ET
|
Vifor Pharma Ltd.
body { font-family: Arial, Verdana, Helvetica; font-size: 13px;}
table.hugin { border-color:black;}
td.hugin { padding: 3px; border-color:black;}
The EFFECT-HF study evaluated the...
FDA Approves Supplemental New Drug Application for Veltassa® Removing Boxed Warning Regarding Drug-Drug Interactions
November 28, 2016 01:10 ET
|
Vifor Pharma Ltd.
body { font-family: Arial, Verdana, Helvetica; font-size: 13px;}
table.hugin { border-color:black;}
td.hugin { padding: 3px; border-color:black;}
The updated US label for Veltassa®...
Vifor Pharma leads initiatives to raise awareness of Iron Deficiency - 2nd Global Iron Deficiency Day on November 26, 2016
November 24, 2016 01:29 ET
|
Vifor Pharma Ltd.
body { font-family: Arial, Verdana, Helvetica; font-size: 13px;}
table.hugin { border-color:black;}
td.hugin { padding: 3px; border-color:black;}
According to the World...
Swissmedic approva ALOXI® in Svizzera per la prevenzione della nausea e del vomito indotti da chemioterapia nei bambini
October 25, 2016 01:14 ET
|
Vifor Pharma Ltd.
body { font-family: Arial, Verdana, Helvetica; font-size: 13px;}
table.hugin { border-color:black;}
td.hugin { padding: 3px; border-color:black;}
- L'approvazione svizzera di...
Swissmedic autorise l'utilisation en Suisse d'ALOXI® pour la prévention des nausées et vomissements induits par la chimiothérapie (NVIC) chez les enfants en Suisse
October 25, 2016 01:14 ET
|
Vifor Pharma Ltd.
body { font-family: Arial, Verdana, Helvetica; font-size: 13px;}
table.hugin { border-color:black;}
td.hugin { padding: 3px; border-color:black;}
- L'autorisation en Suisse de...
Swissmedic lässt ALOXI® zur Prophylaxe von Chemotherapie-induzierter Übelkeit und Erbrechen (CINV) bei Kindern für die Schweiz zu
October 25, 2016 01:14 ET
|
Vifor Pharma Ltd.
body { font-family: Arial, Verdana, Helvetica; font-size: 13px;}
table.hugin { border-color:black;}
td.hugin { padding: 3px; border-color:black;}
- Schweizer Zulassung für ALOXI®...
Appointments at the Galenica Group: New management at Vifor Pharma and new Galenica Group CFO designated
October 06, 2016 02:06 ET
|
Vifor Pharma Ltd
GLATTBRUGG, Switzerland, Oct. 06, 2016 (GLOBE NEWSWIRE) -- The Board of Directors of the Galenica Group has designated Stefan Schulze, currently CEO of Vifor Fresenius Medical Care Renal Pharma...
Appointments at the Galenica Group: New management at Vifor Pharma and new Galenica Group CFO designated
October 06, 2016 01:02 ET
|
Vifor Pharma Ltd.
body { font-family: Arial, Verdana, Helvetica; font-size: 13px;}
table.hugin { border-color:black;}
td.hugin { padding: 3px; border-color:black;}
The Board of Directors of the Galenica...
Galenica completes acquisition of Relypsa, strengthening Vifor Pharma's position in cardio-renal therapies
September 02, 2016 01:10 ET
|
Vifor Pharma Ltd.
body { font-family: Arial, Verdana, Helvetica; font-size: 13px;}
table.hugin { border-color:black;}
td.hugin { padding: 3px; border-color:black;}
Combination with Relypsa strengthens...
Galenica announces Expiration of Cash Tender Offer for Shares of Common Stock of Relypsa
September 01, 2016 01:02 ET
|
Vifor Pharma Ltd.
body { font-family: Arial, Verdana, Helvetica; font-size: 13px;}
table.hugin { border-color:black;}
td.hugin { padding: 3px; border-color:black;}
Galenica Group today announced that...